https://www.selleckchem.com/products/Ki16425.html
3weeks (95% CI 7.1, 13.9). Among the 14 patients with measurable disease, 1 patient had a partial response and 4 patients had stable disease. Most of the adverse events were hematologic. While well tolerated with a strong preclinical rationale, the combination of ruxolitinib and trastuzumab did not lead to an improvement in PFS compared to historical control in patients with trastuzumab-resistant metastatic HER2+ breast cancer. While well tolerated with a strong preclinical rationale, the combination of ruxolitinib and trastuzumab did n
Like
Comment
Share
